15.05.2013 18:05 Uhr, Quelle: Wallstreet online

Algeta announces that Xofigo® (radium-223 dichloride) has been approved by the US FDA

Not Intended for US Media New treatment for castration-resistant prostate cancer (CRPC) patients with bone metastases  Xofigo shown in a pivotal phase III trial to significantly improve overall survival  Algeta to host international …

Weiterlesen bei Wallstreet online

Digg del.icio.us Facebook email MySpace Technorati Twitter

JustMac.info © Thomas Lohner - Impressum - Datenschutz